Skip to content

Effects of Physical Exercise Timing On Strength and Cardiometabolic Health

Effects of Physical Exercise Timing On Strength and Cardiometabolic Health

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06063135
Acronym
EPOCH
Enrollment
152
Registered
2023-10-02
Start date
2023-11-21
Completion date
2025-06-24
Last updated
2025-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Physical Inactivity

Brief summary

Physical exercise is well known to improve human health. Current guidelines provide recommendations on the frequency, intensity, type and duration of exercise. However, they do not provide recommendations for the time of day, exercise should be performed. This is surprising considering that the influence of timing of behaviors such as sleep or nutrition as well as the impact of the circadian timing system on health are well documented. Further, there is evidence for diurnal variation in maximum performance which enables individuals to exercise with different intensities at different times of day, which in the long term might affect physical adaptations to exercise. Thus, this research study investigates if exercise timing impacts human health.

Interventions

Two strength training session per week and one endurance training session per week

Sponsors

University of Basel
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
60 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* BMI 18.5 - 30 kg/m2

Exclusion criteria

* Structured resistance training within the last six months * Ongoing shift work * Irregular bedtime (\> 2 hours variation in habitual bed time) * Smoking * Travels across more than two time zones within the last four weeks * Inability to follow the study procedures (e.g. due to language barriers, psychological disorders, dementia, etc.) * Known pregnancy or lactating women * Participation in any other clinical trial within the last four weeks * Medical condition that is a contra indicator for resistance training, endurance training, or exercising until maximum exhaustion including insufficiently controlled blood pressure (systolic \> 170 mmHg, diastolic \> 100 mmHg), ongoing cancer treatment, unstable angina pectoris, uncontrolled bradyarrhythmia or tachyarrhythmia, severe uncorrected valvular heart disease, clinically relevant acute infection, any form of musculoskeletal injury, orthopedic problems or decompensated cardiovascular disease * Insulin dependent diabetes * Participants using metformin

Design outcomes

Primary

MeasureTime frameDescription
Maximum strengthPre-Intervention (i.e. 1 to 28 days before the first training session of the exercise intervention) and Post-Intervention (i.e. 1 to 28 days after the last training session of the exercise intervention)Mean value of the maximum isometric strength assessed at four different times of the day with an isometric mid-thigh pull on a force plate.

Secondary

MeasureTime frameDescription
Glucose controlPre-Intervention (i.e. 1 to 28 days before the first training session of the exercise intervention) and Post-Intervention (i.e. 1 to 28 days after the last training session of the exercise intervention)2-h postprandial area under the curve for glucose after an oral glucose tolerance test
Body compositionPre-Intervention (i.e. 1 to 28 days before the first training session of the exercise intervention) and Post-Intervention (i.e. 1 to 28 days after the last training session of the exercise intervention)total body fat mass assessed with DXA
Cardiorespiratory fitnessPre-Intervention (i.e. 1 to 28 days before the first training session of the exercise intervention) and Post-Intervention (i.e. 1 to 28 days after the last training session of the exercise intervention)VO2max assessed with cardiopulmonary exercise test

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026